^
    3d
    Prognostic significance of RICTOR mutations in EGFR-mutant metastatic lung adenocarcinoma: a retrospective cohort study. (PubMed, Virchows Arch)
    RICTOR mutations were associated with a high-risk subset of EGFR-mutant metastatic lung adenocarcinoma characterized by more aggressive clinical features and worse survival. These findings suggest the need for prospective validation and support the potential integration of RICTOR status into molecular risk stratification frameworks for precision oncology.
    Retrospective data • Journal
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • RICTOR (RPTOR Independent Companion Of MTOR Complex 2)
    |
    BRAF V600E • EGFR mutation • KRAS G12C • EGFR exon 19 deletion • EGFR exon 20 insertion • KRAS G12
    |
    TruSight Oncology 500 Assay
    3d
    Therapeutic Targeting of VEGFR-2, PD-L1, and EGFR-MET Pathways in Non-Small Cell Lung Cancer: Clinical Progress with Ramucirumab, Atezolizumab, and Amivantamab. (PubMed, J Clin Med)
    Ramucirumab, a monoclonal antibody targeting vascular endothelial growth factor receptor-2 (VEGFR-2), has shown a survival benefit when combined with docetaxel in patients with previously treated advanced NSCLC. Collectively, these agents highlight the expanding role of antibody-based therapies in NSCLC and underscore the importance of biomarker-driven patient selection and treatment personalization. Ongoing research into resistance mechanisms, predictive biomarkers, and combination approaches is expected to further refine the integration of antibody-based strategies in precision oncology for NSCLC.
    Review • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • KDR (Kinase insert domain receptor)
    |
    EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation
    |
    Tecentriq (atezolizumab) • docetaxel • Cyramza (ramucirumab)
    4d
    Design, synthesis and biological evaluation of 2,4,5-trisubstituted 7H-Pyrrolo[2,3-d]pyrimidine derivatives as potent EGFR tyrosine kinase inhibitors against the C797S acquired resistance mutation. (PubMed, Bioorg Med Chem)
    The C797S mutation in the epidermal growth factor receptor (EGFR) presents a significant challenge in treating non-small cell lung cancer (NSCLC), as it confers resistance to osimertinib...In vivo antitumor activity studies demonstrated that LN-B72 significantly inhibited tumor growth. This work establishes a promising foundation for developing novel therapeutic strategies targeting NSCLC patients with the C797S mutation.
    Preclinical • Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R • EGFR T790M • EGFR exon 20 insertion
    |
    Tagrisso (osimertinib)
    6d
    OMAE: Observational Multicenter Study in Patients Receiving Chemotherapy and Amivantamab for Metastatic Non-small Cell Lung Cancer (clinicaltrials.gov)
    P=N/A, N=100, Recruiting, GFPC Investigation
    New trial
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR exon 20 insertion • EGFR exon 20 mutation
    |
    Tagrisso (osimertinib)
    10d
    Whole exome sequencing of lung cancer in Indian patients reveals driver genes and novel mutations with therapeutic potential. (PubMed, Indian J Surg Oncol)
    These findings underscore the value of WES in uncovering clinically relevant mutations and support the integration of genomic profiling into precision oncology strategies for Indian lung cancer patients. The online version contains supplementary material available at 10.1007/s13193-025-02359-9.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • TP53 (Tumor protein P53) • RB1 (RB Transcriptional Corepressor 1) • KMT2D (Lysine Methyltransferase 2D) • LRP1B (LDL Receptor Related Protein 1B) • FBXW7 (F-Box And WD Repeat Domain Containing 7) • KMT2C (Lysine Methyltransferase 2C) • MUC16 (Mucin 16, Cell Surface Associated) • PIK3CG (Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Gamma) • ARID2 (AT-Rich Interaction Domain 2) • FAT4 (FAT Atypical Cadherin 4) • MUC4 (Mucin 4, Cell Surface Associated) • UBXN11 (UBX Domain Protein 11) • CDC27 (Cell Division Cycle 27)
    |
    TP53 mutation • KRAS mutation • EGFR mutation • BRAF mutation • EGFR exon 19 deletion • EGFR exon 20 insertion • EGFR exon 20 mutation
    13d
    ORIC-114 in Combination With Subcutaneous Amivantamab in Patients With EGFR Exon20 Insertion Mutant NSCLC (clinicaltrials.gov)
    P1, N=76, Recruiting, ORIC Pharmaceuticals | Trial completion date: May 2027 --> Dec 2027 | Trial primary completion date: May 2026 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation
    |
    enozertinib (ORIC-114) • Rybrevant Faspro (amivantamab and hyaluronidase-lpuj)
    17d
    Telisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurable, Non Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=60, Recruiting, Jonsson Comprehensive Cancer Center | Not yet recruiting --> Recruiting
    Enrollment open
    |
    MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR exon 20 insertion • MET overexpression • EGFR exon 20 mutation
    |
    CONFIRM anti-Total c-MET (SP44) Rabbit Monoclonal Primary Antibody • VENTANA® MET (SP44) RxDx Assay
    |
    Tagrisso (osimertinib) • Emrelis (telisotuzumab vedotin-tllv)
    19d
    Acquired CD74-ROS1 fusion-mediated osimertinib resistance successfully treated with osimertinib and crizotinib: a case report. (PubMed, J Chemother)
    The combination of osimertinib and crizotinib resulted in a marked clinical and metabolic response, was well tolerated, and the patient remained in remission. This rare case highlights that acquired CD74-ROS1 fusions may contribute to osimertinib resistance and suggests that combination targeted therapy may represent a potential therapeutic approach in selected patients.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • CD74 (CD74 Molecule)
    |
    EGFR mutation • EGFR T790M • EGFR exon 20 insertion • ROS1 fusion • EGFR exon 20 mutation
    |
    Xalkori (crizotinib) • Tagrisso (osimertinib)
    22d
    A Phase Ib Study to Evaluate the Safety and Preliminary Efficacy of IL6-receptor Antibody Sarilumab in Combination With antiPD1 Antibody Cemiplimab for Patients With Non-small Cell Lung Cancer. (clinicaltrials.gov)
    P1, N=56, Active, not recruiting, M.D. Anderson Cancer Center | Trial primary completion date: Jan 2026 --> Jan 2028
    Trial primary completion date
    |
    STK11 (Serine/threonine kinase 11)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • EGFR exon 20 mutation
    |
    Libtayo (cemiplimab-rwlc) • Kevzara (sarilumab)
    24d
    Clinical outcomes of a quadruplet regimen (immunotherapy, chemotherapy, anti-angiogenic therapy) in non-small cell lung cancer with EGFR exon 20 insertion mutations: a case series. (PubMed, AME Case Rep)
    All were grade one to two, with no discontinuations due to toxicity. This small case series describes preliminary antitumor activity and a manageable safety profile with the quadruplet regimen in EGFR ex20ins-mutated NSCLC, warranting further investigation.
    Clinical data • Journal • IO biomarker
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation